Researchers from the University of British Columbia in Vancouver reported a significantly reduced risk for cardiovascular events among patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) who are on hydroxychloroquine.
Medication lowered the risk for cardiovascular events among patients with rheumatoid arthritis
